GSK sells liver disease drug candidate to Alfasigma for $690m
Posted:
Italy-based Alfasigma will acquire worldwide development, manufacturing, and commercialisation duties for linerixibat, GSK’s ileal bile acid transporter (IBAT) inhibitor being developed for cholestatic pruritus in primary biliary cholangitis (PBC).
GIANT Health is delighted to welcome XR Therapeutics to GIANT Health 2026 as part of the NHS Innovation Accelerator (NIA) Pavilion, where they will showcase how immersive technology is helping transform mental health care across the NHS.
Mental health services…
GIANT Health is pleased to welcome Psyomics to GIANT Health 2026 as part of the NHS Innovation Accelerator (NIA) Pavilion, where they will showcase their innovative approach to improving mental health services through better information, earlier understanding and more informed…
Attendees
Sponsors and Exhibitors
Contact us